NCT02673736

A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor

A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects With Advanced Solid Tumors and in Subjects With Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT)

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 11 (actual)
• Sponsor: Plexxikon · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to evaluate safety, pharmacokinetics and preliminary efficacy of the investigational drug PLX73086 in subjects with solid tumors including subjects with locally advanced or refractory tenosynovial giant cell tumor (TGCT).

Conditions

• Solid Tumors
• Tenosynovial Giant Cell Tumor
• Synovitis, Pigmented Villonodular

Interventions

Type	Name	Description
DRUG	PLX73086

Timeline

• Start date: 2016-02-01
• Primary completion: 2018-01-01
• Completion: 2018-01-01
• First posted: 2016-02-04
• Last updated: 2018-08-02

Locations

3 sites across 1 country: United States